Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer

Genetics and Molecular Research

Volumn 13, Issue 4, 2014, Pages 8913-8924

  Han, Y ^a   Yu, D P ^a   Zhou, S J ^a   Song, X Y ^a   Li, Y S ^a   Xiao, N ^a   Liu, Z D ^a   Sun, X J ^b   Zhao, Q Y ^a   Liu, S K ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Department of Thoracic Surgery   (China)

Author keywords

Clinical characteristics; Mutation; Non small cell lung cancer; Oncogene; Radical resection

Indexed keywords

B RAF KINASE; BETA TUBULIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MESSENGER RNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN BRAC1; PROTEIN RRM1; PROTEIN STMN1; PROTEIN TOP2A; PROTEIN TUBB3; THYMIDYLATE SYNTHASE; THYROID TRANSCRIPTION FACTOR 1; TUMOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUBB3 PROTEIN, HUMAN; TUBULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DNA DETERMINATION; EXON; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; RADICAL RESECTION; SEX RATIO; SMOKING; TUMOR DIFFERENTIATION; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TRANSCRIPTION FACTORS; TUBULIN;

EID: 84908542013     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.October.31.6     Document Type: Article

References (38)

1. Anonymous (2009). Clinical Practice Guidelines in Oncology for NSCLC. V2. National Comprehensive Cancer Network 2009.
2. Anonymous (2010). Clinical Practice Guidelines in Oncology for NSCLC. V2. National Comprehensive Cancer Network 2010.
3. Bachman KE, Argani P, Samuels Y, Silliman N, et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3: 772-775.
4. Bepler G, Kusmartseva I, Sharma S, Gautam A, et al. (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24: 4731-4737.
5. Berghmans T, Mascaux C, Haller A, Meert AP, et al. (2008). EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer 62: 35-44.
6. Bhattacharjee A, Richards WG, Staunton J, Li C, et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98: 13790-13795.
7. Boukovinas I, Papadaki C, Mendez P, Taron M, et al. (2008). Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 3: e3695.
8. Boutros PC, Lau SK, Pintilie M, Liu N, et al. (2009). Prognostic gene signatures for non-small-cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 106: 2824-2828.
9. Gately DP and Howell SB (1993). Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer 67: 1171-1176.
10. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, et al. (2004). Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappa B pathway and cellular transformation. Cancer Res. 64: 3428-3435.
11. Jackman DM and Johnson BE (2005). Small-cell lung cancer. Lancet 366: 1385-1396.
12. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, et al. (1995). Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55: 1407-1412.
13. Kanters SD, Lammers JW and Voest EE (1995). Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur. Respir. J. 8: 1389-1397.
14. Kitamura H, Yazawa T, Sato H, Okudela K, et al. (2009). Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. Endocr. Pathol. 20: 101-107.
15. Larsen JE, Pavey SJ, Passmore LH, Bowman R, et al. (2007). Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 28: 760-766.
16. Li Y, Zhang X, Hu T, Han L, et al. (2014). Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. Oncol. Rep. 33: 853-859.
17. Lord RV, Brabender J, Gandara D, Alberola V, et al. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8: 2286-2291.
18. Lowy DR and Willumsen BM (1993). Function and regulation of ras. Annu. Rev. Biochem. 62: 851-891.
19. Mountain CF (1997). Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717.
20. Mountain CF (2002). Staging classification of lung cancer. A critical evaluation. Clin. Chest Med. 23: 103-121.
21. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, et al. (1991). Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br. J. Cancer 63: 237-241.
22. Nitiss JL (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9: 338-350.
23. Olaussen KA, Dunant A, Fouret P, Brambilla E, et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355: 983-991.
24. Rosell R, Scagliotti G, Danenberg KD, Lord RV, et al. (2003). Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553.
25. Rosell R, Danenberg KD, Alberola V, Bepler G, et al. (2004). Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10: 1318-1325.
26. Sculier JP, Paesmans M, Libert P, Bureau G, et al. (1997). Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party. Rev. Mal. Respir. 14: 445-449.
27. Sequist LV, Martins RG, Spigel D, Grunberg SM, et al. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26: 2442-2449.
28. Sève P, Mackey J, Isaac S, Trédan O, et al. (2005). Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 4: 2001-2007.
29. Sève P and Dumontet C (2008). Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9: 168-175.
30. Shintani Y, Okimura A, Sato K, Nakagiri T, et al. (2011). Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann. Thorac. Surg. 92: 1794-1804.
31. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, et al. (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19: 4298-4304.
32. Suda K, Onozato R, Yatabe Y and Mitsudomi T (2009). EGFR T790M mutation: a double role in lung cancer cell survival? J. Thorac. Oncol. 4: 1-4.
33. Sun Z, Wigle DA and Yang P (2008). Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J. Clin. Oncol. 26: 877-883.
34. Tsuboi M, Ohira T, Saji H, Miyajima K, et al. (2007). The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann. Thorac. Cardiovasc. Surg. 13: 73-77.
35. Uesaka T, Shono T, Kuga D, Suzuki SO, et al. (2007). Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J. Neurooncol. 84: 119-129.
36. Vastag B (2005). For EGFR research, new targeted drugs mean new questions. J. Natl. Cancer Inst. 97: 628-630.
37. Yang CH, Yu CJ, Shih JY, Chang YC, et al. (2008). Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol. 26: 2745-2753.
38. Yasumatsu R, Nakashima T, Uryu H, Ayada T, et al. (2009). Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy 55: 36-41.